Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Keio Prof. Kenya Honda Becomes Scientific Advisor for 4BIO
July 14, 2020
- Tecentriq Fails to Improve PFS in Ovarian Cancer: Roche/Chugai
July 14, 2020
- Treakisym Filed for Triple Therapy in DLBCL
July 14, 2020
- 23 Drug Makers to Invest US$1 Billion in “AMR Action Fund” to Develop 2-4 New Antibiotics by 2030
July 14, 2020
- Takeda Looks to Derive 70%-Plus of Japan Sales from 5 Focus Areas by FY2025, Revamp HR Systems
July 13, 2020
- Eisai Joins Forces with Four Universities on R&D of Lupus Drug
July 13, 2020
- Bayer Revving Up Cell Therapy Drive with First Focus on Parkinson’s, Japan Biz Also Eyed: R&D Chief
July 10, 2020
- Yoshiaki Aono to Be Promoted to Chairman and President of Nippon BI in September
July 10, 2020
- Maruho’s Nemolizumab Hits Primary Goal in Japanese PIII for Itching in Atopic Dermatitis
July 10, 2020
- Xofluza Effective for Post-Exposure Prophylaxis of Influenza: Japan PIII
July 10, 2020
- Astex’s Inqovi Gets Approval in US, Canada: Otsuka
July 9, 2020
- Eisai Files Tazemetostat for Follicular Lymphoma in Japan
July 9, 2020
- Eisai’s Sleep Inducer Dayvigo Accepted in Hong Kong
July 9, 2020
- Lenvima-Keytruda Combo’s 1st Line HCC Bid Nixed in US after Rival Nod
July 9, 2020
- Patient Numbers Remain Down at Over 60% of Hospitals Even after Emergency Lifted: Survey
July 9, 2020
- Aducanumab Filing Completed in US; Talks with Japan/EU Regulators Ongoing
July 9, 2020
- Medicago, GSK Team Up to Develop Adjuvanted COVID-19 Vaccine, PI to Commence in Mid-July
July 9, 2020
- GSK in Quest for Best COVID-19 Vaccine, Not the First: Japan Chief Lirette
July 8, 2020
- Sales Rep Promotions in May Tank 67% YOY: Intage
July 8, 2020
- Japan Ethical Drug Sales Slide 12.0% in May: Crecon
July 8, 2020
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…